1. NCCN. Clinical practice guidelines in oncology. Breast cancer V.I: National comprehensive cancer network. http://www.nccn.org/professional/physician_gls/f_guidelines.asp (2009).
2. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672–85.
3. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17(2):460–9.
4. Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25:4414–22.
5. • von Minckwitz G, Kaufmann M, Kümmel S, et al. Definition and impact of pathological complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. Results from the German neoadjuvant meta-analysis. [abst 1028]. Presented at ASCO Annual Meeting 2011, Chicago Illinois June 3rd–7th 2011. This reference illustrates that all pCR are not equal for predicting overall survival and disease-free survival and that the hormone receptor status and tumor grade impact the prognostic strength of a pCR.